Mrs Ashley R Holland, in Cleveland, TN - Licensed Vocational Nurse

Mrs Ashley R Holland, is a Licensed Vocational Nurse based in Cleveland, Tennessee. Mrs Ashley R Holland is licensed to practice in Florida (license number PN5221362) and her current practice location is 3415 Fleeman Place Dr Ne, Cleveland, Tennessee. She can be reached at her office (for appointments etc.) via phone at (863) 651-3364.

NPI number for Mrs Ashley R Holland is 1376240044 and her current mailing address is 3415 Fleeman Place Dr Ne, Cleveland, Tennessee. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1376240044.

Contact Information

	Mrs Ashley R Holland,
	3415 Fleeman Place Dr Ne, Cleveland, TN 37323-1001
	(863) 651-3364
	Not Available

Provider's Profile

Full Name	Mrs Ashley R Holland
Gender	Female
Speciality	Licensed Vocational Nurse
Location	3415 Fleeman Place Dr Ne, Cleveland, Tennessee
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1376240044
Provider Enumeration Date: 02/13/2023
Last Update Date: 02/13/2023

Medical Identifiers

Medical identifiers for Mrs Ashley R Holland such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1376240044	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
164X00000X	Licensed Vocational Nurse	PN5221362 (Florida)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mrs Ashley R Holland is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mrs Ashley R Holland, 3415 Fleeman Place Dr Ne, Cleveland, TN 37323-1001 Ph: (863) 651-3364	Mrs Ashley R Holland, 3415 Fleeman Place Dr Ne, Cleveland, TN 37323-1001 Ph: (863) 651-3364

News Archive

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 annual meeting in Boston, MA.

Buck scientists develop a predictive model to help identify people at risk for severe COVID-19

Researchers at the Buck Institute analyzed data from the COVID-19 Symptom Tracker app used by 3 million people in the United Kingdom, adding the use of immunosuppressant medication, use of a mobility aid, shortness of breath, fever, and fatigue to the list of symptoms and comorbidities that increase the risk for severe COVID-19.

Research on SARS-CoV-2 and dendritic cells may explain why virus is so virulent

In a recent study released on the bioRxiv* preprint server, the researchers suggest that an aberrant inflammatory reaction associated with COVID-19 could be a result of escape from direct sensing by toll-like receptors (TLRs). Moreover, the researchers indicate that this phenomenon might underlie the lack of efficient immunity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) early during infection.

FDA grants tentative approval for Hi-Tech Pharmacal's generic Combigan ANDA

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.

Mrs Ashley R Holland, - Licensed Vocational Nurse in Cleveland, TN